116434-95-8

Basic information

• Product Name: 5-fluoro-3,4-dihydroquinolin-2(1H)-one
• Synonyms: 5-fluoro-3,4-dihydroquinolin-2(1H)-one;5-FLUORO-3,4-DIHYDRO-2(1H)-QUINOLINONE
• CAS NO: 116434-95-8
• Molecular Formula: C9H8FNO
• Molecular Weight: 165.1643232
• Mol File: 116434-95-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-fluoro-3,4-dihydroquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-3,4-dihydroquinolin-2(1H)-one(116434-95-8)
• EPA Substance Registry System: 5-fluoro-3,4-dihydroquinolin-2(1H)-one(116434-95-8)

Safety Data

• Hazardous Substances Data: 116434-95-8(Hazardous Substances Data)

Upstream product

• 132715-74-3 3-(2-Fluoro-6-nitrophenyl)propanoic acid 
• 1247021-77-7 2-(2-amino-6-fluoro-benzyl)-malonic acid diethyl ester 
• 769-10-8 1-fluoro-2-methyl-3-nitrobenzene 
• 1958-93-6 2-(bromomethyl)-1-fluoro-3-nitrobenzene 
• 620550-97-2 diethyl 2-[(2-fluoro-6-nitro-phenyl)methyl]propanedioate 
• 372-19-0 meta-fluoroaniline 
• 100638-26-4 3-chloro-N-(3-fluoro-phenyl)-propionamide 

Relevant articles and documents

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using the compounds.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.

DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12/

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, R8, R9, R10, R11, R12/

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).